Skinbiotherapeutics Share Discussion Threads

[bobalot] 27/11/2017 18:46

People like you and the other OPTI fanatics have never yet posted anything about SkinBio --- BUT YOU TROLL OFTEN....that speaks volumes.






loungeact 27 Nov '17 - 20:51 - 1004 of 1004    1   0 (Filtered)

JUST AN IDIOT ON A THREAD --- WITH HIS OWN AGENDA AND NOT CONSTRUCTIVE DISCUSSION.

get back on your sofa ....lol@TROLL

[owenmo] 27/11/2017 17:26

Same old news from Bobalot; posted several times now eh?

[loungeact] 27/11/2017 13:02

Same old news from Bobalot. Reposted several times over.
Same old news from Bobalot. Reposted several times over.
Same old news from Bobalot. Reposted several times over.
Same old news from Bobalot. Reposted several times over.
Same old news from Bobalot. Reposted several times over.
Same old news from Bobalot. Reposted several times over.

[bobalot] 27/11/2017 12:53

Informing with factual information, like this quote from an interview just this month:

Human trials

Earlier this week SkinBioTherapeutics said it expects a study in people of a cosmetic skin care cream next year to be the start of ‘serious’; commercialisation talks.

Tentative discussions have already begun, said CEO O’Neill, but human data is crucial to the process. 

“Human data is gold dust. The results of the study will spark a major value inflexion point from which we can start serious conversations about commercialisation.”

In the release Thursday, the company said it was confident of human studies getting underway next year.



loungeact 27 Nov '17 - 13:02 - 1001 of 1001    0   0 (Filtered)

NEWS WITH INSIGHTS ---NOT FOR SHORTERS THOUGH

[elrico] 27/11/2017 12:47

Indeed old news and nothing expected until the next update next year. Don't expect a flurry of news. Cath has a very different view on updating investors than SOH.

[bobalot] 27/11/2017 09:44

HERE IS SOME EXCELLENT RECENT NEWS that shows the company is making a lot of progress with its three platforms.

Dr Catherine O’Neill, CEO of SkinBioTherapeutics, commented:

“Since announcing that the SkinBiotix platform passed the key cytotoxicity test in October, we have been focussing on further proving its efficacy."

“With this news today, the technology has passed the three necessary toxicity tests showing that it can be safely applicable across our three target markets."

“We are continuing formulation development and are confident about starting our human studies in 2018.”


loungeact 7 Nov '17 - 12:15 - 998 of 998    0   0 (Filtered)

highly relevant news for new investors knuckle-head

[slartybartfaster] 26/11/2017 17:59

I dont care what the fso spelt out. Without your email identify the question it looks like the sfo is as stupid as you. I dont think that is possible. Given your history this past week i doubt anyone will take you seriously, so ramping on the back of jj is pointless. We already know jj have been involved with uom long before the ipo. According more trustworthy sources, elrico and riskybusiness, jj have been collaborating with uom since 2014 to present day. All this is in the header someuwin posted.

[slartybartfaster] 26/11/2017 13:25

Bob nobody has seen your email. Can you not read or are you being selective because as has already been shown, the email from the sfo is out of context or as i said, we have a sfo as stupid as you. Is that even possible? People are more likely to take vatpaul more seriously than you. Brilliant research vatpaul. Can i follow you.

[bobalot] 26/11/2017 12:48

This is a useful news source for those interested in Microbiome News:

[bobalot] 26/11/2017 12:46

The SBTX patents are going to be very valuable with high demand from the big brand names.

How the Microbiome Could Transform Your Skin in Surprising Ways

Hint: It has the potential to combat acne, eczema and more. Learn how Johnson & Johnson is harnessing the power of bacteria in innovative ways to help keep skin healthy—starting in infancy.
By Magdalena PuniewskaJuly 09, 2017

There’s been a lot of buzz in the news lately about the microbiome—the ecosystem of trillions of microorganisms that co-exist in and on us and that may be responsible for keeping us healthy.

Johnson & Johnson’s interest in the microbiome can actually be traced to the turn of the century. In 1887, it was the first company to mass-produce sterile gauze, cotton and surgical dressings—all of which helped shield patients from harmful bacteria. As a direct result, survival rates in American hospitals started to climb.

“From what we know today, having these beneficial organisms—and having a diversity of them—helps maintain the skin’s defense barrier, which protects us from infections,” explains Kimberly Capone, Ph.D., Research Fellow, Johnson & Johnson Consumer Research & Development. “This means making sure Johnson & Johnson Consumer's products are effective but also gentle, so they don’t wipe out the microorganisms we need but rather encourage them to stay and continue to reproduce to keep our skin healthy.”

In May, to foster more research on this topic, Johnson & Johnson Innovation sponsored a "microbiome challenge," asking researchers to pitch their most forward-thinking ideas. The grand prize: a year of access to JLINX, a Johnson & Johnson Innovation incubator for early-stage healthcare start-ups based in Beerse, Belgium.

Meanwhile, Phagelux, Inc.—a biotechnology company focused on the development and commercialization of so-called bacteriophage-derived technologies that selectively eliminate “bad" bugs while leaving the healthy microbiome intact—recently announced that it has reached an agreement with Johnson & Johnson Consumer Inc. to collaborate on the development of one or more products to improve skin health via the microbiome.

And that’s just scratching the surface of what the company has been up to recently when it comes to studying the potential health and beauty benefits of good bacteria. We look at the many ways Johnson & Johnson is at the forefront of improving skincare—courtesy of the microbiome.


Starting a Healthy Skincare Regimen—in Infancy

When Capone started Johnson & Johnson’s Consumer Microbiome Research Program in 2009, she and fellow scientists began their research work by looking at the skin profiles of the Johnson's® brand’s tiniest users—babies.

“Moms were always interested in boosting their baby’s immunity and resistance to infection,” Capone explains. “Since then, we’ve been looking at how the skin microbiome evolves through life, and how our products, routines and rituals are compatible with that.”


In March, Capone and her team presented a study at the annual meeting of the American Academy of Dermatology showing that, over the course of the first month of life, the microbial diversity of infant skin is significantly increasing. The use of a Johnson's regimen of baby wash, baby shampoo and baby lotion did not negatively affect that healthy evolution.

Translation: “It means we are providing products that are not affecting the natural development of the skin microbiome in infancy,” Capone explains.


In a recent trial of Aveeno® Eczema Therapy Moisturizing Cream, patients with eczema saw a 50% improvement in their condition after two weeks of use. Researchers also noted a jump in microbial diversity on their skin.

[vatpaul] 26/11/2017 12:41

no point posting general information with a view to ramping this dog with fleas pls

[bobalot] 26/11/2017 12:34

Microbiome-Centric Human Health: A Call for Systems Biology

The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps in developing personalized microbiome-based therapies. 


FREE Webinar
Wednesday, November 29, 2017
2:30-4:00 PM Eastern Time
Register Now


With 100 times the number of genes contained in the human genome, and an array of different cell types and functions, one can argue that members of our microbiome constitute an additional human organ system. Research to date has implicated microbial activity in autoimmune disease, cancer, and the obesity epidemic.

As a major source of variability across people, understanding and altering an individual’s microbiome is both a challenge and novel avenue for personalized medicine and nutrition. For a detailed look at the progress made toward understanding the host-microbiome interplay and the efforts undertaken to achieve a steady state of mutualism for a larger human health benefit,

The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps in developing personalized microbiome-based therapies. Attendees will have the opportunity to interact with experts, ask questions, and seek advice on topics related to their research.
Topics to be covered:

Mechanisms by which human microbiota influence health and disease
How multidimensional data are being employed to develop personalized therapies

[bobalot] 26/11/2017 12:29

THE EMAIL FROM SBTX HAS BEEN POSTED ON THIS THREAD FOUR TIME.

TRY READING IT.

[slartybartfaster] 25/11/2017 20:51

Rant, you lippy brat. Filtered am i. Yeah ok little liar pants on fire.
Show us your email that prompted a reply. Until we see your email it looks out of context or the fso is as stupid as you and that is a concern for me.

[loungeact] 25/11/2017 12:25

Bobalot still making things up I see..

[bobalot] 25/11/2017 10:35

THOSE STATED FACTS have been confirmed by SBTX themselves.

Thus they are correct but the OPTI mob expecting free stock refuse to accept the reality on the ground.


loungeact 25 Nov '17 - 12:25 - 984 of 984    0   0 (Filtered)

WRONG AGAIN -- LEGALLY BINDING FACTS ARE NOT WRONG

[bobalot] 25/11/2017 10:33

RISKY --- OPTI HAVE A MAJOR SHAREHOLDING NOT A MAJORITY SHAREHOLDING.

OPTI OWN 41%, OTHERS OWN 59%.

OPTI is classed as an associate with no legal leverage over the BoD or any decision making.

WITH ALL THE HUFFING AND PUFFING FROM a bunch of OPTI shareholders they still don't understand the legalities.

I have laid out the legal boundaries of share ownership, 50% needed for SBTX to be a SUBSIDIARY, 52% NEEDED FOR OPTI to have a controlling interest, and 75% needed for total control at the exclusion of shareholders.

The legal hurdles as I have already said is in Anti Trust Legislation and Insider dealing laws.

[slartybartfaster] 24/11/2017 22:37

This is why i dont believe it will be a double bagger nevermind a multi bagger for years. I have a very small holding in sbtx because i wanted in early. Im losing 30% now. Im not concerned because this will be added for free with the divi. I will add after christmas or around the new isa season because i dont think there is any rush. Sbtx dont seem to have much of a story to tell right now, they are almost secrete in comparison to opti.